120
Participants
Start Date
August 31, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
September 30, 2027
Psilocybin
Participants randomized to the psilocybin microdosing intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of psilocybin daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
Placebo
Participants randomized to the placebo intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of placebo daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
William Osler Health System, Brampton
Providence Care Hospital, Kingston
St. Joseph's Healthcare, London
South Lake Regional Health Centre, Newmarket
Bruyere Health, Ottawa
The Ottawa Hospital, Ottawa
McGill University Health Centre, Montreal
Lead Sponsor
Bruyère Health Research Institute.
OTHER